HAEMONETICS CORP HAE
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms "we," "us," "our," "Haemonetics" and the "Company" mean Haemonetics Corporation.
We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, "Plasma" includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. "Blood Center" includes blood collection and processing devices and disposables for plasma, red cells and platelets. "Hospital" is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. Financial information concerning these segments is provided in Note 18, Segment and Enterprise-Wide Information, within the consolidated financial statements in Item 8 of this Annual Report on Form 10-K.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993.2M | $870.5M | $988.5M | $967.6M | $903.9M | $886.1M |
| Cost of revenue | $546.4M | $611.9M | $617.5M | $553.6M | $487.7M | $472.6M | $504.0M | $550.0M | $492.0M | $507.6M |
| Gross profit | $787.6M | $749.0M | $691.5M | $615.1M | $505.5M | $397.8M | $484.5M | $417.5M | $411.9M | $378.5M |
| R&D | $59.8M | $62.7M | $54.4M | $50.1M | $46.8M | $32.9M | $30.9M | $35.7M | $39.2M | $37.6M |
| SG&A | $442.4M | $436.8M | $429.8M | $376.7M | $340.1M | $275.2M | $282.0M | $273.5M | $316.5M | $301.7M |
| Total operating expenses | $630.9M | $527.1M | $526.7M | $459.1M | $424.8M | $308.1M | $381.2M | $334.0M | $355.8M | $397.9M |
| Operating income | $156.7M | $221.8M | $164.9M | $156.0M | $80.8M | $89.7M | $103.4M | $83.5M | $56.2M | -$19.4M |
| Pre-tax income | $128.0M | $212.1M | $151.9M | $141.4M | $63.6M | $72.9M | $87.2M | $73.6M | $59.6M | -$27.5M |
| Income tax | $30.7M | $44.4M | $34.3M | $26.0M | $20.3M | $6.6M | $10.6M | $18.6M | $14.1M | $1.2M |
| Net income | $97.3K | $167.7K | $117.6M | $115.4M | $43.4M | $79.5M | $76.5M | $55.0M | $45.6M | -$26.3M |
| EPS, basic | 2.06 | 3.33 | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 |
| EPS, diluted | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 |
| Shares, diluted (wtd. avg.) | $47.4M | $50.7M | $51.4M | $51.4M | $51.4M | $51.3M | $51.8M | $52.9M | $53.5M | $51.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $245.4M | $306.8M | $178.8M | $284.5M | $259.5M | $192.3M | $137.3M | $169.4M | $180.2M | $139.6M |
| Receivables | $216.9M | $202.7M | $206.6M | $179.1M | $159.4M | $127.6M | $165.2M | $185.0M | $151.2M | $152.7M |
| Inventory | $306.4M | $365.1M | $317.2M | $259.4M | $293.0M | $322.6M | $270.3M | $194.3M | $160.8M | $176.9M |
| Total current assets | $834.9M | $935.0M | $768.9M | $769.7M | $756.0M | $693.5M | $603.6M | $576.1M | $521.2M | $510.0M |
| Property, plant and equipment | $305.8M | $284.1M | $311.4M | $310.9M | $258.5M | $217.6M | $253.4M | $344.0M | $332.2M | $323.9M |
| Goodwill | $656.4M | $604.3M | $565.1M | $466.2M | $467.3M | $466.4M | $210.7M | $210.8M | $211.4M | $210.8M |
| Other intangibles | $447.7M | $455.7M | $406.1M | $275.8M | $310.3M | $365.5M | $133.1M | $127.7M | $156.6M | $177.5M |
| Total assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B | $1.27B | $1.27B | $1.24B | $1.24B |
| Accounts payable | $51.1M | $67.0M | $73.4M | $63.9M | $58.4M | $50.3M | $50.7M | $63.4M | $55.3M | $43.0M |
| Short-term debt | $5.0M | $303.6M | $10.2M | $11.8M | $214.1M | $17.0M | $77.0M | $27.7M | $194.3M | $61.0M |
| Total current liabilities | $282.6M | $578.1M | $300.4M | $251.8M | $442.3M | $253.5M | $274.8M | $235.8M | $384.7M | $211.2M |
| Long-term debt | $1.22B | $921.2M | $797.6M | $754.1M | $559.4M | $690.6M | $305.5M | $322.5M | $59.4M | $253.6M |
| Retained earnings | $279.3M | $352.2M | $360.5M | $253.2M | $202.4M | $158.0M | $78.5M | $161.4M | $266.9M | $289.9M |
| Total equity | $796.3M | $820.8M | $960.0M | $818.0M | $749.4M | $731.7M | $587.1M | $667.9M | $752.4M | $739.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $293.2M | $181.7M | $181.8M | $273.1M | $172.3M | $108.8M | $158.2M | $159.3M | $220.3M | $159.7M |
| Depreciation and amortisation | $61.2M | $60.0M | $55.8M | $51.2M | $44.4M | $43.1M | $76.6M | $76.8M | $57.7M | $66.5M |
| Stock-based compensation | $33.8M | $29.6M | $28.3M | $25.6M | $24.4M | $25.5M | $20.5M | $17.2M | $13.0M | $9.2M |
| Capital expenditure | $32.8M | $39.3M | $38.1M | $191.3M | $96.5M | $37.0M | $48.8M | $119.0M | $74.8M | $76.1M |
| Investing cash flow | -$179.5M | -$161.9M | -$322.4M | -$143.8M | -$86.3M | -$425.4M | -$57.2M | -$116.1M | -$63.0M | -$73.3M |
| Financing cash flow | -$178.5M | $108.8M | $38.2M | -$100.4M | -$15.7M | $367.5M | -$131.2M | -$50.6M | -$120.6M | -$60.4M |
| Buybacks | $175.0M | $225.0M | $0 | $75.0M | $0 | $0 | $175.0M | $160.0M | $100.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000313143-26-000074.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |